ChemotherapyFDA-approvedFirst-line
Adriamycin
Generic name: doxorubicin
How it works
Interferes with DNA replication in cancer cells, causing cell death and preventing growth.
Cancer types
Breast Cancer— All patients
Efficacy
Studies show that Adriamycin can induce a complete response in around 20% of patients, with a median overall survival of approximately 30 months.
Side effects
Severe
This treatment carries a higher risk of serious side effects. Close medical monitoring is required throughout treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| New Biomarker for Heart Damage from Cancer Treatment | Breast Cancer | phase-2 | — | Source → |
| New Nanocarriers for Delivering Cancer Medicine | Breast Cancer | lab-study | The nanocarriers exhibited pronounced pH-dependent doxorubicin release and enhanced cytotoxicity toward MCF-7 cells (IC₅₀ = 0.8 ± 0.1 μM) | Source → |
| Doxorubicin Resistance Found in Leukemia Cells Grown in Lab | Leukemia | lab-study | Only 0.26±0.21% of the resistant cells entered late apoptosis after 24h doxorubicin exposure. | Source → |
| Researchers Find Link Between Protein and Adriamycin Resistance in Breast Cancer | Breast Cancer | lab-study | — | Source → |
| Cadmium-based Complex Loaded with Doxorubicin Shows Promise Against Leukemia | Leukemia | lab-study | — | Source → |
| Targeted Cancer Treatment Shows Promise for Colorectal Cancer | Colorectal Cancer | lab-study | DOX-P exhibited superior antitumor activity against colorectal cancer than that of DOX. | Source → |
| STK32C and Doxorubicin Resistance in Triple-Negative Breast Cancer | Breast Cancer | lab-study | — | Source → |
| Targeted Cancer Therapy Using Smart Nanosystem | Breast Cancer | lab-study | — | Source → |
| New Compound Enhances Effectiveness of Cancer Treatment in Lab Experiments | Breast Cancer | lab-study | — | Source → |
| Hypertension and Heart Failure in Breast Cancer Patients | Breast Cancer | observational | The RAS inhibitor group had a lower risk for primary outcome (adjusted HR = 0.78, 95% CI = 0.65-0.94) and death (adjusted HR = 0.81, 95% CI = 0.66-0.99) compared to the non-HT group. | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.